Mandate

Vinge advises Air Liquide Santé International on the acquisition of NordicInfu Care AB

March 11, 2013

Vinge is advising Air Liquide Santé International in connection with its acquisition of NordicInfu Care AB. Air Liquide Santé International is Europe’s leading and the world’s third largest company within home healthcare and provides treatment for patients with chronic diseases, such as Parkinson, COPD (Chronic Obstructive Pulmonary Disease) and diabetes. Air Liquide Santé International posted revenues of EUR 2.5 billion in 2012 and has 10,000 employees. Air Liquide Santé International is a division within the publicly listed French group Air Liquide.

NordicInfu Care AB is a leading company in the Nordic countries within home infusion therapy for patients with chronic diseases such as Parkinson, PAH (Pulmonary Arterial Hypertension) and diabetes and had a turnover in 2012 of approximately EUR 22 million. Through the acquisition, Air Liquide Santé International expands its home healthcare activities to the Nordic market, where presence up until now has been limited.

The Vinge team advising Air Liquide Santé International includes partner Jesper Ottergren and associate Ida Christiansson. Furthermore, among others, associates Lynn Andersson Wall and Charlotta Cronér (employment law), Rickard Vernet (competition law), Johan Cederblad (regulatory matters) and counsel Maria Schultzberg (tax) have assisted in the transaction.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025